Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

196
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
196
Urinary Bladder01:23

Urinary Bladder

1.1K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

238
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
238
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

10
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
10
The Micturition Reflex01:26

The Micturition Reflex

799
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
799
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

248
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
248

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<b>First report of the genus <i>Colastomion</i> Baker, 1917 (Hymenoptera: Braconidae) from the Indian mainland and Andaman Islands with description of two new species</b>.

Zootaxa·2026
Same author

<b>Additions to the genus <i>Petalocephala</i> Stål from India (Hemiptera: Cicadellidae: Ledrinae), with description of two new species</b>.

Zootaxa·2026
Same author

A Global Consensus Conference on Surgical Management of Primary Uterovaginal Prolapse and Lower Urinary Tract Dysfunction: Combining Evidence with Expert Opinion.

International urogynecology journal·2026
Same author

Nonconserving locally disordered exclusion process under constrained resources.

Physical review. E·2026
Same author

Translation of chronic pelvic pain experience into patient treatment preference profiles with Q-methodology.

American journal of obstetrics and gynecology·2026
Same author

Does Cartilage Protein Distribution Vary Across Anatomical Regions of the Femur and Tibia in Osteoarthritic Knees? Insights from Proteomic Analysis.

Indian journal of orthopaedics·2026

Related Experiment Video

Updated: Aug 4, 2025

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.3K

STOMp: sexual function trial of overactive bladder medication.

Allison Polland1, Jennifer Joy Hamner2, Divya Arunachalam3

  • 1Department of Surgery/Urology, Maimonides Medical Center, Brooklyn, NY 11220, USA.

Sexual Medicine
|April 3, 2023
PubMed
Summary
This summary is machine-generated.

Overactive bladder (OAB) treatments impact female sexual function. Beta-agonists (BAGs) improved sexual function, while anticholinergics (ACHs) worsened it, suggesting differential effects in OAB therapy.

Keywords:
anticholinergicsbeta-agonistfemale sexual functionoveractive bladder

More Related Videos

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.4K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K

Related Experiment Videos

Last Updated: Aug 4, 2025

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.3K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.4K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K

Area of Science:

  • Urology
  • Pharmacology
  • Sexual Medicine

Background:

  • Female sexual function can be affected by overactive bladder (OAB).
  • Previous research indicates OAB treatment may improve sexual function.

Purpose of the Study:

  • To compare the effects of anticholinergics (ACHs) and beta-agonists (BAGs) on female sexual function in women with OAB.

Main Methods:

  • Prospective multicenter cohort study.
  • 157 sexually active women with OAB were enrolled.
  • Participants completed the Female Sexual Function Index (FSFI) before and after 12 weeks of OAB treatment (ACH or BAG).

Main Results:

  • The BAG group showed improvement in overall FSFI and pain, while the ACH group experienced worsening arousal.
  • Postmenopausal women in the BAG group reported significant improvements in overall sexual function, desire, arousal, and orgasm.
  • The study was underpowered due to participant drop-out, but trends were observed.

Conclusions:

  • Beta-agonist (BAG) treatment for OAB was associated with improved female sexual function.
  • Anticholinergic (ACH) treatment for OAB was linked to a worsening of sexual function aspects.
  • Findings suggest OAB treatment choice may influence sexual health outcomes.